KIT and melanoma: Activation of the MAPK pathway in KIT-mutated melanoma is seen in vivo in tumors, which exhibit activation of both MEK and ERK at baseline and upon treatment, suggesting that the MAPK pathway may be activated independently of KIT in these tumors.